The Clinical Current

FDA Signals Movement on Peptides, But Not Full Approval

The U.S. Food and Drug Administration has scheduled a July 23 to 24, 2026 Pharmacy Compounding Advisory Committee meeting to review several peptide-related substances for possible inclusion on the 503A bulks list. Substances under discussion include BPC-157, KPV, MOTS-C, Semax, and others.

Here is the reality. This is not FDA approval of peptides as drugs. It is a regulatory review that could allow certain peptides to be used in compounding under specific conditions.

Why this matters If even a subset of these peptides moves forward, expect increased clinical usage, higher testing demand, and more scrutiny around compliance. This creates opportunity, but only for labs that clearly understand the regulatory boundaries.

If interested in participating in an upcoming round table discussion on emerging changes (Peptides, Psychadelics) in the lab and research space, contact John Castelino @ [email protected]

CMS April Updates Are Now Live and Already Impacting Labs

Centers for Medicare & Medicaid Services implemented its April 2026 updates affecting the Clinical Laboratory Fee Schedule and CLIA-related edits.

Key changes include new proprietary lab codes, discontinued codes, and updated CLIA edit requirements effective April 1, 2026.

Why this matters This is where margins quietly disappear. If coding, billing, and compliance are not aligned, denials increase and cash flow slows. Labs that stay tight operationally protect revenue. Labs that do not will feel it quickly.

Stay in front of changes, contact John Castelino @ [email protected] or Jason Heffner @ [email protected] to discuss optimization of test and panels to fit medical necessity and alignment with billing.

CLFS Reporting Cycle Will Shape Future Reimbursement

CMS confirmed the next private payor data reporting period runs from May 1 through July 31, 2026, using data collected from early 2025.

There is no reimbursement reduction in 2026. However, beginning in 2027, reductions can reach up to 15 percent annually.

Why this matters

This is not just reporting. It directly influences future reimbursement rates. Labs that understand and manage this process will protect long-term revenue. Labs that treat it as administrative work will pay for it later.

Stay in front of changes, contact John Castelino @ [email protected] or Jason Heffner @ [email protected] to discuss optimization of test and panels to fit medical necessity and alignment with billing.

FDA Expands Use of Real-World Evidence in Diagnostics

The U.S. Food and Drug Administration continues to show increased acceptance of real-world evidence, including the use of laboratory data and medical records in regulatory decisions.

Recent examples include diagnostic submissions supported by real-world datasets alongside traditional clinical evidence.

Why this matters The value of a specimen is no longer just the sample. It is the data attached to it. Labs that can connect specimens with structured clinical data will play a larger role in research, validation, and regulatory pathways.

To understand how you may be able to support the future of clinical research with remnant samples and data capture, reach out to David Curley @ [email protected]

Increased Fraud Scrutiny Is Raising the Bar for Everyone

The Centers for Medicare & Medicaid Services continues to push aggressive oversight initiatives targeting fraud in areas like genetic testing and telemedicine-driven ordering.

Regulators are actively seeking more visibility into billing practices, ordering patterns, and documentation.

Why this matters Even well-run labs will face more scrutiny. Compliance is no longer a back-office function. It is a front-line business requirement that directly impacts growth and partnerships.

Have confdence in your molecular testing provider. Contact Jason Heffner @ [email protected] to discuss why ENDO Lab and Medical Systems is a solid choice.